Our previous studies have shown that atacicept (TACI-IgG) effectively reduces B cells in lupus-prone mice by binding a portion of the receptor TACI to block the effects of survival factors BAFF (B-cell activation factor) and a proliferating-inducing ligand (APRIL) [26]. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.